Senesco Technologies

This past week Senesco Technologies (SNT AMEX) filed its first investigational new drug application (IND) with the US FDA. This is a milestone in the progression of the company from primarily an agricultural focus to a life-sciences company focused on treating cancer, diabetes and cytokine related diseases. The company will enter the clinic in a phase 1B/2A trial once the application is approved. We understand that the Mayo Clinic initially, and possibly other facilities, will test the effectiveness of SNT’s new lead drug candidate SNS01 – T.

Written by Michael A. Berry, Ph.D. - [ Discovery Investing Web Site ]